Rachel K. King - 17 Jun 2022 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
Director
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Issuer symbol
NVAX
Transactions as of
17 Jun 2022
Net transactions value
$0
Form type
4
Filing time
21 Jun 2022, 20:46:49 UTC
Previous filing
14 Jun 2022
Next filing
06 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +700 +11% 6,950 17 Jun 2022 Direct F1
holding NVAX Common Stock 1,100 17 Jun 2022 See Footnote F2
holding NVAX Common Stock 1,100 17 Jun 2022 See Footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -700 -100% $0.000000* 0 17 Jun 2022 Common Stock 700 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2 Represents shares attributable to the Reporting Person as indirect holdings held in a trust for the benefit of the Reporting Person's child.
F3 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 17, 2021 grant date subject to continued service on the Company's Board of Directors through the vesting date.